Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Metastatic RCC to the Pancreas
  2. Adjuvant Sorafenib for RCC at Intermediate or High Risk of Relapse
  3. Laparoscopic CN Is Associated With Significantly Improved Survival Compared With Open CN or Targeted Therapy Alone
  4. Development of a Novel Prognostication Model for Patients With Metastatic RCC Receiving First-Line Molecularly Targeted Therapy
  5. Exploratory Analysis of the Platelet-to-Lymphocyte Ratio Prognostic Value in the Adjuvant RCC Setting
  6. Real-World Safety and Efficacy of Nivolumab for Second- and Later-Line Treatment of Metastatic RCC
  7. Quality-Adjusted Survival With First-Line Cabozantinib or Sunitinib for Advanced RCC in the CABOSUN Randomized Clinical Trial (Alliance)
  8. A Pan-Cancer Analysis of PBAF Complex Mutations and Their Association With Immunotherapy Response
  9. Gender Differences in the Clinical Management of RCC
  10. Key Takeaways From ESMO: Immunotherapy for Renal Cell Carcinoma

Elsewhere

Recently Updated